S H Kelkar and Company Limited (SHK) Earnings Call Transcript
February 9, 2026
Earnings Call Speaker Segments
Good day, ladies and gentlemen, and welcome to the earnings conference call for SH Kelkar and Company Limited. <<operator_script>> We ask that you be aware this conference is being recorded. At this point I'll turn the conference over to Mr. Anoop Poojari of CDR India. Thank you, and Mr. Poojari, the floor is yours.
Thanks, and good afternoon to all of you for being with us on the Q3 and 9M FY 2026 earnings conference call of SH Kelkar and Company Limited. Joining us today are Mr. Kedar Vaze, our Whole-Time Director and Group CEO, along with Mr. Jagdish Agarwal, the Group CFO of the company. Management will start things off with opening remarks, and after that we will open the floor for a question-and-answer session. Just before we get going, please note that certain statements on today's call could be forward-looking in nature, and a disclaimer covering this has been included in the earnings presentation that was shared with you earlier. At this point, I'd like to hand things over to Kedar for his opening remarks.
Good afternoon, everyone. Just to make sure the details are in order, I would also like to mention that Mr. Ramakrishnan, CEO of Fragrances, Asia and U.S.A., is with us on the call as well. So with that, good afternoon, everyone. Thank you for joining our earnings call. On behalf of the management team, I'm happy to welcome Jagdish to his first earnings call with the company. He brings over 28 years of experience across manufacturing, telecommunications, banking, along with a strong record in strengthening financial governance, driving operational efficiencies and supporting business transformations. His appointment reinforces the company's focus on enhancing financial discipline and execution capabilities. Jagdish will begin with the overview of the financial performance and outline the key financial priorities. Over to you, Jagdish.
Thank you, Kedar. Good afternoon, everyone, and thanks for being with us on SH Kelkar's earnings call covering the third quarter and the 9 months of financial year 2026. To start, I want to say how glad I am to be at SH Kelkar at a moment when the business is putting money behind building its next growth phase. As the biggest flavor and fragrance company of India origin, with a global footprint that keeps getting larger, this is a leadership business with strong customer relationships and deep capabilities. And in my own view, there is a significant opportunity here to further sharpen execution and financial outcomes as time goes on. With that as background, let me take you through how we performed financially in the period and lay out the key priorities from a finance standpoint, and after that I'll return the call to Kedar so he can share his view on where the company is heading strategically. Over the 9 months ended, the company posted consolidated revenue of INR 1,718 crores, which works out to a Y-o-Y growth of 10% even though conditions were challenging in operation across some markets. Demand has stayed resilient in our core categories, helped by continued traction with customers both existing and new. Our performance in the quarter was somewhat softer, reflecting a subdued environment and a slower ramp-up in certain product categories.
Looking at margins, our gross margin was largely steady in the quarter. The EBITDA margin, though, showed where we are in the current execution phase, with costs tied to scaling strategic initiatives and building up organizational capabilities. Adjusted, so leaving out the effect of new growth-led investments and elevated insurance costs, EBITDA margin came in at roughly 13%. A major focus for me will be sharpening how we handle cash flow and manage the balance sheet. As we move through this investment phase, debt levels could rise in the near term, in line with our strategic initiatives and capacity expansion plans. That said, we see room to make working capital more efficient, and that will be a key lever for bolstering balance sheet strength and bringing leverage down over time. Another priority is lifting our cash conversion and getting better translation of operating results into bottom line performance, backed by cost discipline, tighter capital allocation and better working capital execution. Maintaining discipline and well-prioritized capital deployment across the business will stay an important focus as we keep investing for growth. These initiatives will take time to fully play out, but our approach will be structured and disciplined, and the benefits should emerge progressively over the medium to long term.
And I mean, it's only been about 2 months in these organizations, and whatever small insights I've gathered, I feel our focus is in the right place. We're investing for the future. Often, we don't see quarter-to-quarter improvement, but the initiatives laid across the organizations to drive future sustainable, profitable growth are definitely going to pay out. It's a matter of time — maybe medium term to near future, we see these growth initiatives playing in favor of the company. With that, I'll now hand over the call to Kedar for his comments.
Thank you, Jagdish. To add to what he said, the investments we're making now are designed to get the company ready for its next growth phase—particularly in the worldwide fragrances and flavors market—by reinforcing our global creative development centers, adding capacity, and putting money into capabilities that sharpen innovation, execution, and customer engagement, above all in new markets like USA, U.K. and Europe. As we discussed before, one main goal behind these investments is to boost our competitiveness and our positioning. The markets where we're investing at present include U.K., Germany, U.S., UAE, and together they make up nearly 75% of the global fragrance market, whereas India accounts for a comparatively modest share of around 5%. The domestic market keeps presenting appealing growth opportunities that we expect to capture on the back of underlying FMCG growth, and at the same time, growing and scaling our footprint in these international markets gives us access to a substantially bigger opportunity over time and supports a more balanced growth profile. We understand this is an organic build-out and that it will take time, with a horizon of over 2 to 3 years, as capabilities scale and customer relationships deepen. Our experience in the Flavors business, where earlier investments are now turning into stronger growth, gives us confidence that a similar trajectory can unfold in Fragrances over time.
Within that wider plan, we've seen promising movement in the U.S. In the quarter, our creative development center there booked its inaugural customer order — a significant milestone as we enter the biggest flavor and fragrance market globally. Though it's still an early step, talks with customers have been positive, and the center is being woven more and more into our worldwide innovation and delivery setup so it can serve both regional clients and other multinational ones. On the strength of our 102-year heritage, we are now constructing a sturdier, more scalable operating platform, with gains anticipated to build gradually as our capabilities mature. We think this point in the cycle is the right one for investing with conviction. As these capabilities grow, they will sharpen our capacity to seize opportunities, bolster our competitive standing, and let us generate steady value creation for many decades ahead. With that, I'd like to ask the moderator to open the floor for questions.
<<operator_script>> Our first question comes from Jatin Chawla, who is calling in from RTL Investments.
To start off, I want to ask about something you brought up both in your opening remarks and in the presentation — the idea that now is the right moment to put money into this growth initiative. When you describe this as the right time to invest, what exactly do you have in mind?
When you take a look at how the global competitive landscape stands, a couple of the big players — IFF and Firmenich in particular — have done major M&A deals over the last few years, and at this point they're kind of reorganizing themselves, and that opens up a chance for midsized companies and the next tier down to expand into these markets. What we observe is that the market is over-consolidated, with 3 or 4 players, and the business opportunity increasingly sits with a large number of smaller clients in direct-to-consumer online and e-commerce businesses that are coming along — or taking over, or starting up, in many regions of the world. We see the landscape of opportunity, both in terms of resources and in terms of the chance for mid and small clients around the world, at a very opportune moment. This is sort of the point in the cycle where new green shoots show up in the FMCG business.
Understood — that helps a lot. My follow-up question is this: early in the year, you said gross margins would take a hit during the first half, but that in the second half we'd begin to see things get better. Yet when I look at your gross margins for the December quarter, they're very close to what they were in the first half. So is this now the normal level for gross margins, or do you expect an improvement? And if an improvement is coming, when should we expect it on gross margins?
Let me split this into two parts. First, there's gross margin improvement tied to raw material availability and supply. As you know, sales came in slightly muted relative to what we initially expected for this quarter, so some of that gross margin improvement will move into the following quarter as raw material bought at the older prices gets consumed. So on an underlying, like-for-like basis, gross margins have improved. This quarter, certain business, Global Ingredients in particular, faced a bit of negative headwinds, and that weighed on overall gross margins. But from a raw material standpoint, we see gross margin stabilizing and improving. Probably starting with the Jan, Feb, March quarter, we will see improvement, or definitely from April onwards, we will be back at a very strong gross margin level. Currency exchange rates have also dampened some of the Indian rupee businesses from a gross margin standpoint. While dollar prices have come down, rupee prices have not fallen as much as we expected a few months ago.
Is it reasonable to expect a return to the 45% gross margin level we enjoyed previously, or will that require additional time?
My view is that the 45% we saw last year was largely the raw material up cycle, when we got a really strong jump. It should keep getting better gradually, but whether it gets to 45% or ends up just a bit below that — there are simply too many variables at play, from geopolitics to currency and so forth. So I'd rather not comment on that. Directionally, I'd say gross margins are improving across the board, and we will see the benefit come through. So at 42.4% or thereabouts, we're sitting at the low end of the gross margin range this business will operate in.
Alright, and one final question. India has signed several trade agreements with the U.K., the EU, and also with the U.S. — some kind of deal has been signed there too. So is there any benefit we as a company see coming from these deals?
It's a little early to say for sure. Once we get the fine print and grasp the dynamics of whether anything has shifted for our industry or related ones, then we'll be able to comment. So having these FTAs announced and in the news is good news. The fine print is — the devil is in the details, so as soon as we have the detail, we'll know whether there's any specific benefit we'll derive out of this.
The next question comes from Dhaval Shah of Girik Capital.
Sir, my question really concerns how capital is being allocated. So if you could help us get a picture of the last 2 years and of what lies ahead — how much capital have we put to work, and how much more do we intend to put to work, across the different geographies in what we call the center of excellence, given that you see a great deal of opportunity in those countries? So if you break it down among the U.S., Europe, and India, at the various locations where you see plenty of opportunity, how much capital has been deployed, and how much more do you plan to deploy there? That is my first question.
All right, I’ll address that. So regarding capital deployment, you’re referring to CapEx. And as for CapEx, when I examine it...
Right, so regarding CapEx or acquisitions, here's what we've done. In Europe, for instance, we've put in INR 80 crores up to now, correct? And also, yes, I mean the spending you incur on R&D and CapEx, yes. So both — anything involving big money that isn't bringing in revenue right away, that kind of spending. Yes.
Alright, so looking beyond India, we've had CapEx underway in Europe, and we've committed roughly EUR 7 million to EUR 8 million there. A significant portion of that work is already complete. So over the coming 6 to 12 months, I don't see much outflow from India. We're expecting it to land in the EUR 2 million to EUR 3 million range, that's our current expectation. Turning to what's happening within the country, as you know, we had a fire 2 years ago, and 2 of our facilities in Maharashtra — Vanavate and Vashivali — are currently in the construction phase, and that outflow will continue. But for outside India, the anticipated outflow should fall between EUR 2 million and EUR 3 million, while India should come in somewhere between INR 70 crores and INR 80 crores.
Regarding India CapEx, you're looking for somewhere between INR 70 crores and INR 80 crores — and over what period would that be?
We expect that to happen over the next 12 to 18 months.
Right, so, somewhere between 12 and 18 months out. Got it. And every bit of that is being directed toward rebuilding Vashivali?
There are 2 facilities, Vashivali and Vanavate.
Yes. All right. Those 2 facilities. Understood. And what comes after that?
To build on that point, once the new second facility is completed, one of the older facilities will be shut down, and some operating savings on lease and other items will come down. So OpEx costs will go down.
All right, got it. So these are the two...
This facility is a replacement, and the second one is a new facility that will take the place of the old one in Mumbai.
Got it. So in Europe, that's another EUR 2 million to EUR 3 million, which works out to roughly INR 25 crores to INR 30 crores, and INR 80 crores over in India. So all told, we're looking at INR 110 crores to INR 120 crores that we'll be putting in across the coming 2 years, correct, from the balance sheet?
Yes, we can put that at somewhere between 12 and 18 months from today.
Somewhere between 12 and 18 months. All right. And here in the U.S., what's the amount we've invested up to now, aside from developing centers or any other CapEx in the U.S.?
In the U.S., our development center is also already established and is more or less up and running. We're beginning work at our leased facility for production. However, for the development center, we had invested approximately $1.5 million. $1.5 million to $2 million. Somewhere in the range of USD 1.5 million to USD 2 million.
Understood. Is there any additional spending on the U.S. side?
No. So we’re beginning production at this leased facility, so those things will be business as usual. But I don’t believe that whatever we have as of today is going to continue.
Understood. Now, for the second part of your question—the debt figure you referenced in the presentation, the one that will rise slightly. At present, we're sitting at roughly INR 800 crores of debt, with INR 90 crores to INR 100 crores of cash on the books. Looking back over the past 3, 4 years, aside from that big fire we had—which consumed a substantial portion of our cash flows—what's the trajectory from here? I mean, you're going to peak at roughly another INR 100 crores of debt on this—how should we interpret that, since our debt-equity ratio is genuinely getting affected? Meanwhile, on the other side, we're putting money in for growth. But how are you attempting to strike that balance? Because ultimately we're unable to deliver the ROCEs that, as an investor, you'd want to see from this company. It's entirely under—always under pressure. Since I've been following this company for the past couple of years—early on, things were moving in the right direction. We had plans to reach 17%, 18%, 19% kind of EBITDA margin.
That also took place during a handful of quarters in between. And once again, our figures are lower. So could you give us a sense of what kind of time frame we ought to keep in mind when we look at those numbers? What kind of balance sheet across the coming 2 years should we be thinking about? And what kind of ROCEs could it produce? Because we have made a lot of investments. And according to your business plan, where do you see -- where will this company stand 2, 3 years from now?
Given the limited insight and understanding I've gained over the last 2 months, I can speak to a more realistic situation and what I feel. You're right about the debt level — correct, our gross is almost INR 800 crores. And quite frankly, we really need to do a detailed exercise to come back with what the right number will be. But if I look at it — I think it's going to be range bound, maybe somewhere in this range or perhaps 20, 30 plus or minus, that kind of a range, at least in the immediate future; I see 3 to 6 months. For sure, for sure. When you look at the long term, things are definitely going to come back on...
We're still hashing out the detailed plan on this, so I don't want Jagdish to stick his neck out 1 kind of a month into the company. I think we're at 13% adjusted EBITDA as we speak. It'll take 2 years of time for all the investments we have done over this year to start to generate positive cash flow revenues in Europe and America, particularly, including U.K. and these markets. So currently, this quarter, what we call adjusted EBITDA without new initiatives is roughly 13%. I expect that to be 17% over the next 2 years. And we will put out a detailed like a quarter-on-quarter, year-on-year execution plan in a couple of weeks, maybe 4 weeks, 6 weeks as part of our budgeting exercise. I would just say that all the infrastructure that we need to operate is in place and the opportunities are in place. Now we understand that the cash flow and debt situation, we may not be able to take all the opportunities, so we'll need to focus on a few and not -- or defocus or kind of defer our few opportunities. So we will take that up and create a strong growth plan probably by April for the next 3 years.
Understood, sir. And sir, one final suggestion: a number of investors have stayed with the company for quite a while, and following the fire incident and this investment phase, our market cap has also been hit hard. So if the promoter could demonstrate a bit more confidence by doing some creeping acquisition in the company, that would really help restore a great deal of faith in the company. So that is just a small suggestion.
Honestly, I feel that pull every single day. In fact, I've had people tell me the opposite — don't put money in or take it out, just hold things where they are, stay put. Still, at these valuations, the temptation hits me daily. So going forward, we'll certainly be weighing that feedback with greater seriousness.
Yes. And sir, regarding this pledge of 10 lakh shares that was recently created, what prompted that?
This is an old commitment, and the only reason is that the market trade declined — there's a trader...
A trader of shares pledged additional shares. Yes.
To repeat, that gets reversed since the market hasn’t risen. All of these — what I mean is, these are existing loans that are already in place. Those pledged amounts will rise and fall depending on market cap.
Our next question comes from Henil Bagadia, who is calling in from Equicorp Partners.
Sir, just a few questions. Sir, could you also shed a bit more light on the cost in the U.S., both on the fixed cost side — that is, the cost coming from the new creative fragrance center we have and the new leased tolling facility we have there? And how much time will it take, or how many contracts, or what size value contracts will it take to, I mean, reach a breakeven point in the U.S. market?
Ramakrishnan speaking. Essentially, our US investment has come mostly through OpEx rather than CapEx. CapEx involvement is very limited, or there is none. Even the manufacturing facility was taken on an operational lease for 5 years. We've already begun winning business in the US, and our road plan is that by the end of next year, we should be able to win roughly $2 million, $2.5 million worth of business.
What's the fixed cost going to be — I mean, the fixed operating cost for the creative fragrance center facility as well as the leased tolling facility?
Roughly $3.5 million to $4 million.
Alright. Sir, and then second, regarding cash flow — because you're going to invest roughly INR 70 crores to INR 80 crores into Vashivali along with the new replacement unit we had — so this means, we're actually going to file an insurance claim for that, correct? So at first the cash flow will come from our side, and after that we'll submit the insurance claim to check and probably recover most of it from the insurance side, if I'm not mistaken.
Right. So the insurance claim has already been submitted and is being processed, and our expectation is that it will be settled within the coming 6 to 12 months.
There will be some incremental cost for the second facility — likely INR 30 crores to INR 40 crores — but that won't land in the immediate year; it'll come the year after.
And what sort of savings on lease cost would we get — the ones we'll realize from the Mulund facility once we, I mean, should shut it down?
On the Mulund facility lease, we'll be saving somewhere between INR 3 crores and INR 4 crores.
Alright. Sir, one final point regarding Europe. Is that facility up and running? Since I believe the current plant is at 100% utilization, we had in fact been intending to enlarge it and raise capacity because of bottlenecks?
During quarter 4, the new facility should be operational—possibly toward the end of quarter 4, with March being the timeline we currently expect. So in quarter 1, I anticipate that both the new European facility and the new Indian facility will be operational. Then by quarter 2 or quarter 3, they ought to be fully up and running, and as for the older ones, we'll sort of transition between quarter 1 and quarter 3, when both are operating. And at the end of quarter 3 next year—quarter 1 calendar or quarter 4 financial—the new facilities should be taking over the full manufacturing.
Alright. Sir, one final point, just an observation. Since we also work with small and medium-sized players, along with new emerging start-ups that enter e-commerce and are growing their operations, when an acquisition of those particular accounts takes place by any of the large MNCs, what exactly happens after the acquisition? Are they folded into the MNCs' existing supply chain, or are the current vendors supplying fragrance, flavors, et cetera, kept on, with integration occurring periodically.
So regarding integration with a larger company, we’ve got 1 or 2 examples of that kind. There are businesses that Marico has acquired, or that Unilever and others have acquired. Our core business has kept going. In fact, it has grown. We managed to consolidate it and keep growing. So for us, there’s no risk when bigger companies acquire. Some start-ups have suppliers that are much smaller or, let’s say, not professionally organized, and in that case that business offers us an opportunity for additional growth when any small brand is acquired.
Now we'll take our next question, coming from Riddhesh Gandhi at Discovery Capital Management.
I'd just like to get a sense of how we approach this internally when we examine our CapEx and investments—what hurdle rates do we typically use? Are we looking at payback period, equity, IRR? I just want to understand that and how we think about it.
Typically, our benchmark is a 20% hurdle rate, sir. That said, certain strategic bets — the ones we're funding right now, for instance — sit in markets roughly 10x to 12x larger than the space we currently play in. So naturally, relative to the existing business, these outlays are big, and that means a longer gestation period. Even so, we usually assess things at steady state beyond 3 years; that buildup window is the period during which the businesses ought to be delivering 20% ROI or ROCE once those 3 years have passed.
Understood. Sir, one more thing I wanted to get a handle on: clearly this is a sector where customers tend to stay put and where getting in is fairly difficult, and that has clearly benefited our own India business. But when we look at growing beyond India, particularly in the States, will that become an obstacle and a source of difficulty? I simply wanted to hear, based on how clients and customers reacted at first, whether things are going according to plan, better than plan, or worse than plan? That is what I was hoping to understand.
The early feedback, sir, is pretty much according to plan, I'd say. We've got the first orders in hand now. Those should be executed starting in the fourth quarter of this year and continuing from the first quarter of next year onward. The U.S. market — the first external or new market initiative — after 18 months, we're beginning to see business there. In the same way, more business will start coming in for Europe and the U.K. So we're on plan. I think we have a solid read on the market, where there are green shoots, and business cycles also play a part. So there's been a great deal of investment and a great deal of growth with the big FMCG players. And I think globally, and in India too, some of the innovation is now coming from smaller brands that reach the market through e-commerce or a direct-to-customer approach. So a lot of innovation and a lot of small clients are mushrooming, and this is a phase of new green shoots, in a sense. So in a way, it's spring time for the fragrance business. A lot of small businesses are springing up right now.
That gives us a solid chance to reel them in. Existing businesses, as you're aware, tend to stay put. That's why a surge of new businesses starting up is the moment we view as a real opening.
Understood. Sir, the other question was this: historically, if we've observed many of our global competitors posting extremely high ROCEs, even M&As in this space have taken place at fairly rich valuations. Whereas our ROCE at present looks depressed. But in your view, this simply reflects the timing of the CapEx and expansion currently underway, which you believe should normalize over the next year or 2?
Yeah, so I’d say the first factor is the expansion investments. The second is the impact of the fire, and that happened around the same time we were looking at the major expansion. So with the benefit of hindsight — a 2020 hindsight view — we might have phased those expansion investments differently. We made a large expansion bet, and at the same time we’re dealing with the fire incident, which requires attention and CapEx to recover and restore. So I think it’s partly both. If domestic operations had simply been running normally, our financials would not have shown such a large stretch. We’re now well positioned. Although we’re at a low position today, I think the market situation and growth expectations are in place. If you look at the company’s history, we’ve made some organic investments in Europe — inorganic investments in Europe in the past. We have now looked at organic expansion in Southeast Asia, America, the U.K. and Germany. So we’re confident about taking up the entire market without having to overpay or start with an inorganic approach.
I think there’s real confidence that we can turn things around and grow in these markets. A lot of the challenging investments—new molecules, captives, processes, innovation platforms that these markets require—we’ve kept building them over the last 2 decades. We already hold more than 25 patents across all these countries. That gives us a very strong foundation when we enter these markets. We aren’t starting today. The first patents in the U.S., for example, expire in 2030. So we now have only 4 or 5 years to capitalize on this patent cycle before they become public domain, so to speak. We see this as the right opportunity, giving us 5 to 7 years to push technology-based, innovation-based business growth in these markets.
Understood. Sir, what amount of receivables are we anticipating from the insurance? And I just want to get a sense — is this typical? What are the usual timelines for receiving it? And do any risks attach to that?
So we're looking at roughly INR 100 crores, and we don't anticipate any risk there. The exact amount could be a bit more or a bit less, but I think we're fairly confident that we'll receive this money in 6 to 12 months.
Yes, sir, on your second question — when I speak with other companies, the general sense is that yes, it really does take 18, 20 months. In fact, our first claim came in earlier than a lot of other companies in a similar situation. So we're pleased that it has moved along well. We'll keep working at it, making sure it gets done on time and that we obtain the cash flow as soon as we can.
Madhav Marda from Fidelity International has the next question.
What's your view on the top line growth? It's been somewhat softer lately. Are there particular reasons for that? And when do you think it will return to the 12% CAGR that we guide to on a steady-state basis?
Yes. I believe that 12% CAGR remains on track. We did observe some softening early in the year in Europe, at the time when the tariffs and certain geopolitical situations were present. Much of that business weakness stems more from a timing matter. The orders in question were pushed back by a month. So, in the European context, this year is effectively 11 months. Even so, sales are still holding at the same level as before when measured in euro terms. For India, I had expected faster growth and a demand revival in the second half, given the GST changes announced at the start of the year, or in the second quarter of the year. That has not materialized as we anticipated. We did see some uptick around Diwali. Since then, however, we are not witnessing the broad-based jump in demand that we had expected. Regardless, I think our market position is quite strong. We should be able to regain our sales momentum in India fairly soon.
I mean, right now this year we're sitting at roughly 11%. And there's also the first quarter, which had that low base effect. So looking forward, which markets do you figure might perform better? Are there any particular drivers that could push growth up to 12% over the next 2, 3 years?
Middle East, Southeast Asia — all those markets are expanding at a really rapid clip. So for this quarter, by the end of March, 12% looks a bit tough, honestly. But growth is happening — and next year, likely above 12%. That 12% CAGR, I think, remains a long-term figure we expect to grow at.
All right, and I just wanted to verify two additional items. One concerned our margin side — clearly, we intend to front-load OpEx and spending on those developmental initiatives. So for the path toward reaching 17% in 2 years' time, does that come entirely from operating leverage? Or does gross margin play a part as well? For instance, what carries us from, say, 13%, as you just mentioned, up to 17%...
Yeah, so I think gross margin reflects both operating leverage and the gross margin itself. We hit the low point of the cycle last year, and we're improving now. As we move quarter by quarter, gross margin should tick up a bit and operating leverage should come through as well. On top of that, on the operations side—especially in India—once things settle down and we shift production back to our new factory, there are significant logistics and extra costs involved, and we'll kind of return to more efficient operating parameters. So I see all of this as operating leverage plus the new factory ramping up, which ought to help us going forward. The new markets—as we mentioned, the first order in the U.S. We're also seeing green shoots in other markets. So once that really kicks in, we'll see additional improvement in the EBITDA.
Sir, have we hit the highest OpEx level yet for a few of these new initiatives? Or is there additional cost still to come through the P&L?
No, OpEx has topped out. I just want to say — I think the OpEx figure in INR might shift somewhat because of currency fluctuations. But measured in dollars and euros, we've hit peak OpEx. There will be — so when we talk about peak OpEx, there are 20 people, a couple join, a couple leave, and that keeps happening. But no major jump is anticipated. 2%, 3% either way, roughly around those levels.
Then, regarding insurance costs, that was the final question. First, at what point do we anticipate the pending receivables we have not yet gotten from the insurance company? When is that expected? And second, even the insurance cost, which at present is somewhat elevated, when do you foresee it decreasing and returning to a more steady-state level, so to speak?
Yes, we’ve already addressed that — we expect the insurance claim money to come to us within the next 6 to 12 months. And as for the higher premium, maybe — I mean, we’re working on it, but it looks like it could take another year or so.
Sir, how much of the money owed to us is still outstanding from the insurance company?
Our expectation is roughly INR 100 crores, give or take.
And on that higher premium, sir — how much are we actually spending? I mean, the amount above the normal level, the premium that you're paying — what is it?
So we're spending somewhere in the neighborhood of INR 13 crores to INR 13.5 crores more than we typically would in a year.
Our following question comes from Abhijit Akella at Kotak Institutional Equities.
Could you put a number on how much currency movements affected revenue growth in the quarter? Specifically, how much of that growth came from the rupee's depreciation?
Compared with the prior quarter, I’d say there isn’t much difference. Compared with last year, export revenue is up roughly 10%. So that represents a significant increase. In this quarter, however, our European underlying business grew 3% year over year in euro terms.
Understood. That’s useful. Sorry — just on the ROW part of Fragrances, it looks like it has expanded pretty strongly across the 9 months, from roughly INR 215 crores to around INR 282 crores, or something close to that. Are there particular geographies driving that increase? And what’s your view on the outlook for that side of the business?
The Middle East, Africa, and Central Asia are regions where we're experiencing robust growth. That ties in with the markets in those regions expanding in step. So we're seeing solid double-digit growth taking place in the Middle East.
Okay. And Mr. Ramakrishnan was good enough to point out the overall investments on the U.S. side of the business, along with the revenue budget we expect over roughly the coming year. Could you do the same and spell out the investments and the revenue projections for the Europe side — the 2 centers that we're setting up there?
The centers are already established and operational. We've incurred approximately EUR 2.5 million in additional costs at those centers through new initiatives we've launched. That spending will underpin the EUR 45 million to EUR 50 million — roughly that range — that we'll land at this year for the European business. Our new growth factory should be completed during this quarter. By quarter 1, and likely quarter 2, we expect it to reach full operations and stabilize. That provides us with another lever to push market growth aggressively, since at present we're running at nearly 85%, 90% capacity, which means we can't be aggressive across all European businesses when it comes to growth. With the new factory ready, we'll be aggressive on the growth rates we're able to achieve there.
And regarding the rise in employee cost we’re seeing this quarter — INR 93 crores versus INR 85 crores in the prior quarter — is that mostly because of adding headcount? Or does it relate more to foreign exchange movements?
You know, Abhijit, all 3 of those play a part. Part of it comes from adding headcount, part from currency effects, and there's also a bit of a true-up effect in there.
Yes, and I apologize — I skipped the final piece.
The effect of the true-up on what the system contributes.
Fresh labor expense.
All right, that's clear. And going forward, how much more of a rise should we anticipate over the coming quarter or so, before all those investments are baked into the employee cost base?
From an all-in cost standpoint on the new initiative, I'd say this quarter is pretty typical. There isn't any — so every center has its staff in place. You'll notice a few individuals coming aboard, 1 or 2 people shifting around. That's just ordinary churn. That said, we aren't anticipating any really big additions. We do observe some relocation activity among staff since we operate multiple centers — some folks will transfer from one site to another, that sort of thing. Still, on the overall cost impact, I don't foresee additions. What I foresee is reorganization: wherever the opportunity exists, we'll relocate those people.
The next question comes from Debanjana Chatterjee at Spark Capital.
I'd just like to get a clearer picture of how your CDCs connect with the manufacturing facilities. So my impression is that you essentially have 3 growth engines — one is your manufacturing facilities, the second is your CDCs, and the third is your global sales, correct? So does the demand come out of the CDCs, with the products made at your manufacturing facilities and then moved across? Is that how the whole thing operates?
Right. So CDCs are the creation development centers, and inside those centers they collaborate with sales and marketing to build new business. Operations then delivers on that business. So operational growth means CapEx and facilities — manufacturing facilities that back the growth. But the real growth originates from the CDCs. So we have established 3 new initiative CDCs, and those will bring in additional business across different geographies and different customer categories. To serve that business, we have enlarged our manufacturing footprint in Europe as well as in India and Asia.
Sir, if I may ask at this point, what's the total installed capacity for the company overall, and what are the utilization rates?
In Europe, our installed capacity serves the 50 million and runs at roughly 90% utilization. We're going to double that capacity — or at least take it to about 1.5x — during the quarter, meaning this quarter, by the end of this year, or in the first quarter of next year. In India, we currently have, let's say, 20,000 tonnes of capacity. We'll add another 9,000 tonnes in the first quarter of next year, and after that build an additional 15,000 tonnes. Within India we have a good amount of headroom to keep growing. So India has no capacity constraint, while the 2 factories are currently pushing together. And we have additional capacity built in Southeast Asia for 3,600 tonnes, which will give us another 5 million to 7 million of turnover sales in Southeast Asia.
All right. That 12% CAGR you mentioned — over which period does it apply? Does it run from FY '26 through '29, or from FY '26 through '28?
So 2024 through 2025 serves as the baseline, and our growth rate will be 12% year over year.
So that 12% year-over-year growth—with '24-'25 as the base year, is that right?
You've got that right.
Return ratios remain in the single digits, roughly 6% to 7%. Once these things turn, will we see double-digit growth after FY '28? 55
When you say ROCE, are you referring to return on capital employed?
Could you repeat that?
Is ROCE what you mean?
You mentioned both ROE and ROCE. ROE sits in the higher single digits, so will we be looking at something in the mid-teens by FY '28 or '29, once these things stand up?
Yes.
Alright.
For the business, I'm expecting we'll land at roughly 14% in the end.
By FY '29?
Yes. In fact, once the new initiative begins producing cash breakeven in 2 or 3 years, we'll get to 14%.
Okay, and my final question concerns EBIT. What I've been seeing is that across the last couple of years, the EBIT margin for your Fragrance business has stayed in the upper single digits, at roughly 6% to 8%. Meanwhile, Flavors has climbed considerably, reaching 20%, 22%, and it has held there. So will we continue to see EBIT margins of this kind at least through FY '27 and '28, and after that perhaps at growth levels?
On Flavors, as you mentioned, a couple of years ago we made fairly heavy investments and essentially reoriented that business for the next growth phase in India. So Flavors now sits at a steady state. In the India business, we've put all the development center and manufacturing capacity in place that we need. There could be some incremental cost CapEx as we grow, but this is a steady-state business. If we look at Fragrances in India, it's very similar and very steady state. EBIT in Fragrances is depressed right now and looks different because of our investments outside India, and that will take 2, 3 years, 4 years to play out, and we expect it to become more steady state after that. It won't reach the same mature level as the India business, but we expect it to be clocking 13%, 14% EBITDA and improving year-on-year as we add operating leverage.
So you're referring to EBIT here, correct? Because my concern is with the EBIT margins. So for Fragrance, you're saying it will reach 13% to 14% in another 2 to 3 years, roughly.
As those businesses outside India ramp up, it'll be 13% to 14% EBIT.
And what would blended EBIT be, taking into account both India and domestic?
It's EBIT — 17%, 18%, right around that level.
EBIT. So in Fragrance, your blended EBIT comes in at 17% to 18%, correct?
Yes. On an EBITDA basis, we'll be at 17%. Jagdish just corrected me. When I say EBITDA level, I mean 14% and 17%. At the EBIT level, that figure will be 2% to 3% higher.
Starting from the current 8%, correct, when it comes to Fragrance?
Yes.
Right. And this Flavors segment should stay in the neighborhood of 20% to 22%, if I'm not mistaken, since it's holding fairly steady.
Flavor has been holding steady, and right now we're focusing on the India market along with certain export opportunities. Down the road, when we turn our attention to Southeast Asia, the Middle East, or Europe, that's when investment will come. After the Fragrance investments begin to deliver results, we'll be in a position to consider taking the Flavor business global.
Ladies and gentlemen, our final question comes from Bharat Sheth at Quest Investment Advisors -- Managers.
Kedar, you mentioned this — which new factory is going to start, I mean in Q1, and the one that was under fire will start, when do we expect that to begin?
To begin with, the new facility will kick off in Q1, and as for the one affected by the fire, we likely have the <<inaudible>>, and once we move the first factory, then likely next year — either Q1 or Q4 of next year — we'll begin the migration.
All right. And to get a better handle on this gross margin, how much pricing power do we actually have — I mean, enough to offset import values ?
Yes. So the majority of what we sell — 85% of our products — is proprietary. That gives us really strong pricing power, so we're able to pass cost increases along to our clients.
What's the actual problem here that's keeping us from really getting the gross margin up the way you expected?
Honestly, there isn't a genuine problem. Conditions are getting better. What I mean is the figures lag somewhat, but apart from that, conditions are getting better.
I've got one question for Jagdish. There's a certain amount of outstanding GST receivable that you have...
Sir, I apologize for cutting in. Bharat, your line has a great deal of background noise. Could you please relocate to another spot?
Absolutely, happy to.
I understand what you're asking. Your question concerns the GST receivable, is that right?
Correct.
Right, so that’s something we’re actively working on, and I do expect we’ll see some positive movement there within 3 to 6 months.
Yeah. So Bharat bhai, regarding what had been held up — I believe the orders are going our way, and GST refunds have begun arriving. At the peak, about INR 50 crores of GST on exports was tied up either in appeal or awaiting clarity on the basis. I think those GST refunds have started coming through. So it may be each month, or every 2 months, that we receive refunds, and this INR 50 crores should be brought back down to normal levels within a couple of months — perhaps 6 months.
Thanks so much. At this point, I’ll pass the conference back to management for their closing remarks.
Thanks. I hope our responses have addressed your questions in a satisfactory way. If you believe anything still needs clarification, please get in touch with the company, or don't hesitate to reach out to our team or CDR India. Thanks again for spending your time with us on this call.
Much appreciated. Thanks. That brings this conference to a close on behalf of SH Kelkar and Company Limited. We're grateful you joined us, and you can disconnect at this point. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete S H Kelkar and Company Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to S H Kelkar and Company Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.